Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

This study is testing a three-drug combination — Inetetamab (a HER2-targeting antibody), Pyrotinib (a HER2-blocking pill), and Vinorelbine (a chemotherapy drug) — in people with HER2-positive advanced breast cancer that has already been treated. **You may be eligible if...** - You are 18 or older - You have been diagnosed with HER2-positive advanced breast cancer (locally advanced or metastatic) confirmed by lab testing - Your cancer cannot be removed by surgery - Your heart and organs are healthy enough to tolerate treatment - You are willing to use contraception during the study **You may NOT be eligible if...** - Your heart function is significantly impaired (low ejection fraction or abnormal QT interval) - You are pregnant or breastfeeding - You have serious uncontrolled medical conditions - Your cancer is HER2-negative Talk to your doctor to see if this trial is right for you.